Sources: Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine Realworld use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database PMC Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity | Obesity | JAMA Internal Medicine | JAMA Network Semaglutide StatPearls NCBI Bookshelf Safety of Semaglutide PMC Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes PMC Realworld evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP1RAbased weightloss therapies PMC Liraglutide for weight management: a critical review of the evidence PMC Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus PMC Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network

This variability underscores the need for further exploration of how GLP-1 may be associated with neurochemical pathways associated with addiction, particularly dopamine signaling and reward mechanisms
When most people hear ultrasound, their thoughts immediately go to pregnant women and sonograms
Ozempic is the injectable peptide GLP-1 medicine with the most FDA-approved uses in type 2 diabetes, with indications to improve blood sugar along with diet and exercise, to reduce the risk of major cardiovascular events (heart attack, stroke, or death) in adults who also have known heart disease, and to reduce the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults who also have chronic kidney disease.1 Ozempic injection and Ozempic tablets are not approved for use in children.
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews)